VERISANTE TECHNOLOGY
VRS on the tsx venture exchange.
Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer.
The Verisante Aura™ for skin cancer detection and the Verisante Core™ series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and the University of British Columbia and tested and refined on approximately 1,000 lesions at the Skin Care Centre at Vancouver General Hospital.
This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer immediate results for many of the most common cancers.
Verisante is ISO 13485:2003 certified as a medical device manufacturer.
MANAGEMENT TEAM
Thomas Braun
BA, JD, LLM
Chief Executive Officer
President
Prior to founding the company, Thomas Braun practiced corporate securities law at Braun and Co., specializing in representing small high tech public companies. Mr. Braun is experienced in the management of public companies and has conducted dozens of mergers and acquisitions and going public transactions.
Mr. Braun earned a BA degree from the University of Western Ontario, a Juris Doctor (JD) degree from the University of British Columbia, and a Master of Laws (LLM) degree from the University of San Francisco specializing in International Business Transactions. He is a member of the State Bar of California, and the American Bar Association; and is also a member of the Law Society of British Columbia and the Canadian Bar Association. He is also admitted to practice before the Federal Court for the Northern District of California and the Ninth Circuit Court Appeals.
Anna Trinh
B.Comm, LLB
Chief Financial Officer
Corporate Counsel
Anna Trinh obtained a Bachelor of Commerce (Finance) and a Bachelor of Laws degree from the University of British Columbia and was admitted to the British Columbia Bar in August 2007.
Ms. Trinh has over ten years experience in advising OTC and Venture Listed Companies regarding regulatory and other compliance filings, general corporate finance and corporate management matters.
Ms. Trinh is a member of the Law Society of British Columbia, the Canadian Bar Association (BC) and the Canadian Corporate Counsel Association.
PRODUCT DEVELOPMENT TEAM
Dr. Branko Palcic
Ph.D.
Dr. Branko Palcic holds a Ph.D. in Biophysics from McMaster University. He is currently both an Honorary Professor for the Department of Pathology and Laboratory Medicine, and was an Adjunct Professor for the Department of Physics, at the University of British Columbia. He was the founder and Senior Scientist of the Cancer Imaging Department, as well as the Director of Technology Development, with the BC Cancer Agency. Dr. Palcic's research interests include the development of methods for detection, diagnosis, and prognosis of early cancer and precancerous lesions.
Dr. Haishan Zeng
Ph.D.
Dr. Haishan Zeng holds a Ph.D. in Biophysics from the University of British Columbia. He is currently a Senior Scientist in the Integrative Oncology Department (Imaging Unit) at the BC Cancer Agency and also an Associate Professor of Dermatology and Skin Science at the University of British Columbia. Dr. Zeng's research focus is on the optical properties of biological tissues and light-tissue interaction and their applications in medical diagnosis and therapy and is named on numerous patents, including the patents that Verisante Technology has licensed from the BC Cancer Agency.
WEB: verisante.com
PRESS & MEDIA LINK: verisante.com
NEWS RELEASE: verisante.com
CHART: sc |
